PCSK9 and acute coronary syndrome: Most current guidelines recommend starting PCSK9 inhibitors in patients with acute coronary syndrome (ACS) if LDL-C targets are not achieved after 4–6 weeks of maximally tolerated statin and ezetimibe therapy.